{Reference Type}: Journal Article
{Title}: The effect of high-dose selenium on mortality and postoperative organ dysfunction in post-cardiotomy cardiogenic shock patients supported with mechanical circulatory support - A post-hoc analysis of the SUSTAIN CSX trial.
{Author}: Ott S;Dresen E;Lee ZY;Müller-Wirtz LM;Procopiuc L;Ekrami E;Pitts L;Hellner N;Catena D;Duerr GD;Wittmann M;Waeschle RM;Elke G;O'Brien B;Heyland DK;Stoppe C;
{Journal}: J Crit Care
{Volume}: 83
{Issue}: 0
{Year}: 2024 Oct 1
{Factor}: 4.298
{DOI}: 10.1016/j.jcrc.2024.154853
{Abstract}: <B>OBJECTIVE: </B>Cardiac surgery, post-cardiotomy cardiogenic shock (PCCS), and temporary mechanical circulatory support (tMCS) provoke substantial inflammation. We therefore investigated whether a selenium-based, anti-inflammatory strategy would benefit PCCS patients treated with tMCS in a post-hoc analysis of the sustain CSX trial.<BR><B>METHODS: </B>Post-hoc analysis of patients receiving tMCS for PCCS in the Sustain CSX trial, which investigated the effects of high-dose selenium on postoperative organ dysfunction in cardiac surgery patients.<BR><B>METHODS: </B>duration of tMCS therapy.<BR><B>RESULTS: </B>postoperative organ dysfunction and 30-day mortality.<BR><B>RESULTS: </B>Thirty-nine patients were treated with tMCS for PCCS. There was no difference in the median duration of tMCS between the selenium and the placebo group (3 days [IQR: 1-6] vs. 2 days [IQR: 1-7], p = 0.52). Median dialysis duration was longer in the selenium group (1.5 days [0-21.8] vs. 0 days [0-1.8], p = 0.048). There was no difference in 30-day mortality (53% vs. 41%, OR 1.44, 95% CI 0.32-6.47, p = 0.62).<BR><B>CONCLUSIONS: </B>In this explorative study, a perioperative high-dose selenium-supplementation did not show beneficial effects on organ dysfunctions and mortality rates in patients with PCCS receiving tMCS.